Notch, IL-1 and Leptin Crosstalk Outcome (NILCO) Is Critical for Leptin-Induced Proliferation, Migration and VEGF/VEGFR-2 Expression in Breast Cancer

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Guo, Shanchun ^a   Gonzalez Perez, Ruben R ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA LIKE 4 LIGAND; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; JAGGED1; JANUS KINASE 2; LEPTIN; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH4 RECEPTOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN HEY2; SMALL INTERFERING RNA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENIC FACTOR; AUTACOID; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIRC5 PROTEIN, MOUSE; HEY2 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1 RECEPTOR; LUCIFERASE; REPRESSOR PROTEIN; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HEY2 GENE; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; SURVIVIN GENE; UPREGULATION; VASCULOTROPIN GENE; VASCULOTROPIN RECEPTOR 2 GENE; ANIMAL; BIOLOGICAL MODEL; CELL MOTION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-1; LEPTIN; LIGANDS; LUCIFERASES; MAMMARY NEOPLASMS, ANIMAL; MICE; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN-1; RECEPTORS, NOTCH; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79959570695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021467     Document Type: Article

References (45)

1. Cordle J, Johnson S, Tay JZ, Roversi P, Wilkin MB, et al. (2008) A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol 15: 849-857.
2. D'Souza B, Miyamoto A, Weinmaster G, (2008) The many facets of Notch ligands. Oncogene 27: 5148-5167.
3. Guo S, Liu M, Gonzalez-Perez RR, (2011) Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta.1815: 197-213.
4. Rehman AO, Wang CY, (2006) Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 16: 293-300.
5. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR, (2010) Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 1806: 108-121.
6. Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, et al. (2002) Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 33: 863-870.
7. Apte RN, Dotan S, Elkabets M, White MR, Reich E, et al. (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408.
8. O'Neill LA, (2000) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2000.
9. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, et al. (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 100: 2645-2650.
10. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, et al. (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14: 2009-2014.
11. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J, (2002) Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188: 219-226.
12. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, et al. (2006) High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer 118: 1414-1419.
13. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N, (2008) Leptin signaling in breast cancer: an overview. J Cell Biochem 105: 956-964.
14. Hu X, Juneja SC, Maihle NJ, Cleary MP, (2002) Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94: 1704-1711.
15. Bartella V, Cascio S, Fiorio E, Auriemma A, Russo A, et al. (2008) Insulin-dependent leptin expression in breast cancer cells. Cancer Res 68: 4919-4927.
16. Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, et al. (2004) Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett 565: 139-142.
17. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, et al. (2008) Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 68: 9712-9722.
18. Zhou W, Guo S, Gonzalez-Perez RR, (2011) Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer 104: 128-137.
19. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, et al. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339-343.
20. Sweeney G, (2002) Leptin signalling. Cell Signal 14: 655-663.
21. Garonna E, Botham KM, Birdsey GM, Randi AM, Gonzalez-Perez RR, et al. (2011) Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. Plos one 6: e18823.
22. Mehta RS, Harris SR, Gunnett CA, Bunce OR, Hartle DK, (1993) The effects of patterned calorie-restricted diets on mammary tumor incidence and plasma endothelin levels in DMBA-treated rats. Carcinogenesis 14: 1693-1696.
23. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, et al. (2004) Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 229: 182-193.
24. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, et al. (2003) Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 77: 205-215.
25. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, et al. (2006) Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 281: 26320-26328.
26. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, et al. (2009) Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 11: R36.
27. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, et al. (2010) Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 22: 1350-1362.
28. Styer AK, Sullivan BT, Puder M, Arsenault D, Petrozza JC, et al. (2008) Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology 149: 506-514.
29. Carino C, Olawaiye AB, Cherfils S, Serikawa T, Lynch MP, et al. (2008) Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. Int J Cancer 123: 2782-2790.
30. Bash J, Zong WX, Banga S, Rivera A, Ballard DW, et al. (1999) Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J 18: 2803-2811.
31. Osipo C, Golde TE, Osborne BA, Miele LA, (2008) Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 88: 11-17.
32. Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, et al. (2002) Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 1592: 107-116.
33. Garofalo C, Sisci D, Surmacz E, (2004) Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin Cancer Res 10: 6466-6475.
34. Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, et al. (2002) Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord 26: 577-580.
35. Ray A, Nkhata KJ, Cleary MP, (2007) Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol 30: 1499-1509.
36. Altieri DC, (2008) New wirings in the survivin networks. Oncogene 27: 6276-6284.
37. Ryan BM, O'Donovan N, Duffy MJ, (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-562.
38. Iso T, Kedes L, Hamamori Y, (2003) HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237-255.
39. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, et al. (2004) Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 279: 19908-19915.
40. Soares R, Balogh G, Guo S, Gartner F, Russo J, et al. (2004) Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol 18: 2333-2343.
41. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, et al. (2008) Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68: 5226-5235.
42. Ray A, Cleary MP, (2010) Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 14: 443-451.
43. Soares R, Guo S, Gartner F, Schmitt FC, Russo J, (2003) 17 beta-estradiol-mediated vessel assembly and stabilization in tumor angiogenesis requires TGF beta and EGFR crosstalk. Angiogenesis 6: 271-281.
44. Soares R, Guo S, Russo J, Schmitt F, (2003) Role of the estrogen antagonist ICI 182,780 in vessel assembly and apoptosis of endothelial cells. Ultrastruct Pathol 27: 33-39.
45. Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, et al. (2006) The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 66: 8501-8510.